Sana Biotechnology (SANA) Cash from Investing Activities (2020 - 2026)

Sana Biotechnology has reported Cash from Investing Activities for 7 years, with the latest figure at $49.4 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 197.76% year-over-year to $49.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.4 million (down 106.65% YoY) and the FY2025 annual result came in at -$40.2 million, down 330.55% from the prior year.
• Cash from Investing Activities rose to $49.4 million in Q1 2026 per SANA's latest filing, from -$16.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $88.4 million in Q4 2022 and troughed at -$77.2 million in Q1 2024.
• A 5-year average of $24.1 million and a median of $31.9 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 400.02% in 2023, then tumbled 223.12% in 2024.
• Over 5 years, Cash from Investing Activities stood at $88.4 million in 2022, then sank by 82.69% to $15.3 million in 2023, then surged by 207.56% to $47.1 million in 2024, then sank by 135.03% to -$16.5 million in 2025, then soared by 399.69% to $49.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $49.4 million, -$16.5 million, and -$48.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.